<!DOCTYPE html>
<html lang = "en">


<head>
  <meta charset="utf-8" />
  <meta name="viewport" content="width=device-width, initial-scale=1.0, user-scalable=yes" />


  
  <!-- fetch the title & body fonts immediately to avoid re-rendering -->

  <link rel="preload" as="style" href="/static/css/default.css" />


<style>
  @font-face {
      font-family: 'Source Serif Pro';
      font-weight: 400;
      font-style: normal;
      src: url('/font/ssfp/SourceSerif4-Regular.ttf.woff') format('woff');
      src: url('/static/font/ssfp/SourceSerifPro-BASIC-Regular.ttf') format('truetype');
      unicode-range: U+0020-007E, U+2010, U+2013-2014, U+2018-2019, U+201C-201D;
      font-display: swap
  }
  @font-face {
      font-family: 'Source Serif Pro';
      font-weight: 400;
      font-style: italic;
      src: url('/font/ssfp/SourceSerif4-It.ttf.woff') format('woff');
      src: url('/static/font/ssfp/SourceSerifPro-BASIC-RegularItalic.ttf') format('truetype');
      unicode-range: U+0020-007E, U+2010, U+2013-2014, U+2018-2019, U+201C-201D;
      font-display: swap;
  }
  @font-face {
      font-family: 'Source Serif Pro';
      font-weight: 600;
      font-style: normal;
      src: url('/font/ssfp/SourceSerif4-SemiboldIt.ttf.woff') format('woff');
      src: url('/static/font/ssfp/SourceSerifPro-BASIC-Semibold.ttf') format('truetype');
      unicode-range: U+0020-007E, U+2010, U+2013-2014, U+2018-2019, U+201C-201D;
      font-display: swap
  }


  </style>
 

  <meta name="author" content="James Maye" />
  <meta name="title" content="Acute Lymphoblastic Leukaemia">
  <meta name="generator" content="Pandoc">

  <link rel="stylesheet" type="text/css" href="/static/css/default.css" />
  <link rel="icon" type="image/png" href="/static/img/m.png" />
  
  <title>Acute Lymphoblastic Leukaemia · James Maye</title>


</head>



<body>
    <main>
       
<!-- Navbar Goes here -->
        <div id="nav">

            <div id="navbar">

                <div>
                    <a href="/medicine">Medicine</a>
                </div>

                <div>
                    <a href="/">JM</a>
                </div>

                <div>
                    <a href="">Chapter</a>
                </div>


                </div>
            </div> 
<!-- End navbar -->
    	

     <header id="top">
         <h1>Acute Lymphoblastic Leukaemia</h1>
     </header>

     <article>
<!-- Top matter start -->
         <div id="page-metadata">
             <p>
                 <span id="page-description" title="Short summary of article."><em>ALL is the commonest form of cancer in children, with a cure rate of &gt;80%</em></span>
                 <br/>
                 <span id="tags" title="Tags list"><em>
                     <a href="/tags/medicine">medicine</a>, <a href="/tags/haematology">haematology</a>, <a href="/tags/disease">disease</a>, <a href="/tags/cancer">cancer</a>, <a href="/tags/leukaemia">leukaemia</a>
                 </em></span>
                 <br/>
                 <span id="page-metadata-block">
                     
                     <!-- Date created - date modified -->
                     <span id="page-date-range"><span id="page-creation" title="Date page contents were begun."><em>27/02/2021</em></span> &ndash;  <!--endash with space either side--><span id="page-source"><a title="Link to latest revision of the raw Markdown text source for this page, 'Acute Lymphoblastic Leukaemia': acute-lymphoblastic-leukaemia.md" href="acute-lymphoblastic-leukaemia.md"><span id="page-modified" title="Date of last major modification to this page."><em>27/02/2021</em></span></a></span></span>
                     
                     <span id="page-status" title="Status of current page: 'abandoned/notes/in progress/finished'"><em>first draft</em></span>
                </span> <!-- page-metadata-block end-->     
             </p>
             <hr>
         
         </div> <!-- page-metadata end -->
<!-- Top matter end -->
         <div id="md-body">
    
<p>Acute lymphoblastic leukaemia (ALL), is a high-grade <span class="JM-link"><a href="haematological-malignancy">Haematological Malignancy</a></span>. It is the commonest form of cancer in children. Central nervous system involvement is common, requiring prophylactic intrathecal cytotoxic therapy. It is generally curable, with a cure rate of greater than 80% with chemotherapy. ALL is further subclassified based upon immunohistochemistry.</p>
<h2 id="epidemiology">Epidemiology</h2>
<p>It is the commonest form of cancer in children and while it can occur at any age it is predominantly diagnosed under the age of 20, with children under the age of 5 at particular risk.</p>
<h2 id="clinical-features">Clinical features</h2>
<ul>
<li>Pancytopenia
<ul>
<li>Due to bone marrow failure secondary to excessive blast cells</li>
</ul></li>
<li>Bruising
<ul>
<li>Due to thrombocytopenia</li>
</ul></li>
<li>Bone pain</li>
<li>Lymphadenopathy</li>
<li>B Symptoms of systemic disease (Ann Arbor B classification)
<ul>
<li>Fevers</li>
<li>Night sweats</li>
<li>Weight loss</li>
</ul></li>
</ul>
<h2 id="prognostic-factors">Prognostic factors</h2>
<ul>
<li>Age: &lt;1 year or &gt;10 years worsens prognosis. Adults do particularly badly</li>
<li>Highest pretreatment WCC - correlates with tumour load and prognosis</li>
<li>Chromosome abnormalities</li>
<li>Males generally worse prognosis than females</li>
<li>T-cell disease generally worse than B-cell</li>
<li>Response to treatment</li>
</ul>
<p>Treatment response is measured by blast cell count in the marrow. A morphological remission is defined as blast cells making up &lt;5% of the cells in the bone marrow. An alternative assessment is that of minimal residual disease, than uses PCR to amplify clonal rearrangements in tumour-specific genes (immunoglobulin genes in B-cell disease and T-cell receptor genes in T-cell disease). This allows detection of 1 cell in 10,000. Children with persistence above one malignant cell in 10,000 one month into chemotherapy will require a more intensive regime.</p>
<h2 id="management">Management</h2>
<p>Acute lymphoblastic leukaemia is highly curable, with cure rates above 80%. Remission can generally be induced without myelosuppressive chemotherapy. As central nervous system involvement is common, prophylactic intrathecal cytotoxic therapy is used.</p>
<p>Chemotherapy treatment for acute lymphoblastic leukaemia can be divided into distinct phases. During induction, inpatient chemotherapy aims to remove the bulk of leukaemic cells (&lt;5% blasts in marrow). This facilitates the return of normal bone marrow function. This is followed by consolidation therapy, designed to remove residual malingant cells. Following consolidation of remission, a maintenance regime of low dose oral chemotherapy is given for a further 1-3 years. This maintenance regime is specific to ALL.</p>
<p>Stem cell transplantation is used in particularly poor prognosis malignancies. Prior to transplantation, a conditioning therapy of strong chemotherapy and total body radiotherapy kills all of the patient’s bone marrow cells, resulting in complete bone marrow failure. The patient then receives a bone marrow transplant, recolonising the bone marrow with donor cells which then attack any residual malignant cells (graft-versus-leukaemia effect). Stem cell transplantation is a particularly risky treatment, and total body irradiation causes sterility. Because of this, stem cell transplantation is reserved for particulalry poor prognosis cases.</p>
<!-- {BearID:AB5CE725-E221-4DB9-862A-D33721326B7D-1211-000091FFD22C6392} -->

         </div> <!-- div id="md-body" -->
    </article>

</main>
</body>
</html>


